- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
Some people are so proud to live with a leash around their necksthose cheebye mrna cucks still promoting snake oil in 2022.
-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
Sinovac Vax 3rd Dose
- Thread starter Patriotmissile
- Start date
- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
Quoting 158th media. How brilliantYour beloved sinovac made from attenuated whole wild type coronavirus which includes the spike proteins
https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html
China in hard lockdown with no end in sight because they know their garbage doesn't work
https://www.straitstimes.com/asia/e...rnment-come-under-fire-for-shanghais-lockdown
https://www.straitstimes.com/singap...who-got-sinovac-vaccine-than-pfizer-one-study
Anyway life is back to normal for the rest of us. But it's still fun to watch anti vaxxers and anti mRNA wallow in agony of their own doing thanks to their ignorance and stupidity.
Please keep it up
Whole inactivated virus of course include the spike protein but not made via their spike proteinsYour beloved sinovac made from attenuated whole wild type coronavirus which includes the spike proteins
https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html
China in hard lockdown with no end in sight because they know their garbage doesn't work
https://www.straitstimes.com/asia/e...rnment-come-under-fire-for-shanghais-lockdown
https://www.straitstimes.com/singap...who-got-sinovac-vaccine-than-pfizer-one-study
Anyway life is back to normal for the rest of us. But it's still fun to watch anti vaxxers and anti mRNA wallow in agony of their own doing thanks to their ignorance and stupidity.
Please keep it up
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
clearly your knowledge of vaccines comes from reading the 159th media
but keep it up. see how long you can hold out against mRNA booster
- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
Its 160th lol woof woof
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
U still believing the info by pap means u are an idiot. Check the report. Those that took sinovac and sinopharm are the older folks above 60 so regardless of what jabs. They are still at higher risk. Why ppl like u dun have brains?
source of your piece of toilet paper ?
You didn't make it past Sec 1 did you ....?
kum lan. this is done by ur pap. do more research and dun just read the headlines from 160th. u no brains or brains got fogging from mrna?
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac288/6567428?login=false
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
Good heavens .
This is the same paper quoted by ST and it is pro mRNA vaccine and anti Sinovac
You really ought to read the whole paper and not just misinterpret the numbers
But thank you for supporting the efficacy of mRNA vaccines
Who is the moron now ? quod erat demonstrandum as they say in Latin ......
u really kum gong. read the data about the age of those people that took sinos. u are really the idiot. asked for source and i gave u. still wanna argue ur way out of this mess. u really got serious brain fogging.
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
keep going my friendaccidentally quoted the right paper
your stupidity is clear for all to see
accidentally quoted the right paper
your stupidity is clear for all to see
ownself stupid still wanna act smart. people here will know who is the moron here.
clearly mrna causes brain fogging.
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
https://www.straitstimes.com/singap...who-got-sinovac-vaccine-than-pfizer-one-studyownself stupid still wanna act smart. people here will know who is the moron here.
clearly mrna causes brain fogging.
Nah. Your same paper published today in your 158th media and explained in simple layperson terms so even a cretin like you can understand
Thank you for supporting mRNA and the 158th media
Try harder next time
- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
- Joined
- Feb 16, 2020
- Messages
- 2,361
- Points
- 113
LOL. idiot with brain fog still arguing.
I believe the low SES slang for what you just did is : shoot own goal
Selective reading disorder detectedAnother side effect of MRNA
Still ownself think ownself is not an idiot.
- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
Really dont understand these fellas. Already the west says inactivated is useless, yet these bloody French & darn Brits start allowing the introduction of another inactivated Covid19 vaccine. Didn't they learn like some mentally challenged that mrna is the mother of all vaccines
REUTERS
April 14, 202210:04 PM GMT+8Last Updated 6 hours ago
By Natalie Grover
and Sarah Morland
3 minute read
LONDON/PARIS, April 14 (Reuters) - Britain approved Valneva's (VLS.PA) COVID-19 vaccine on Thursday, becoming the first European country to clear the use of the French firm's shot in a move that boosted its shares by more than 20%.
The go-ahead is the sixth COVID vaccine approval by Britain and comes even though London last September scrapped a 1.4 billion euro ($1.5 billion) deal to buy the Valneva shot, alleging the company was in breach of its obligations under the agreement - which Valneva denied.
The company said it was in discussions to supply up to 25,000 doses to the UK's National Health Service and frontline workers in Scotland. It said talks over a settlement following the UK government's decision to ditch its contract continued.
Announcing the approval, the UK's Medicines and Healthcare Products Regulatory Agency (MRHA) said it was the first, whole-virus inactivated COVID-19 vaccine to gain approval in the UK, adding the shot met safety, quality and effectiveness standards.
However demand prospects could be limited in the UK given the vaccination rate is already relatively high, with about 73% of the population having had two doses and almost 60% having had a booster. The government is also rolling out fourth doses to the vulnerable and the elderly.
"The UK continues to have sufficient supply for its vaccination programme," a Department of Health and Social Care spokesperson said.
Still, the regulatory nod is a boost for the company as the European Medicines Agency (EMA) assesses the vaccine for possible approval. The European Commission has signed an advance deal for up to 60 million doses. read more
ADDITIONAL AUTHORIZATIONS
Valneva's stock jumped more than 20% to their highest since Jan. 5, helping recover ground lost so far this year amid uncertainty about the regulatory approval process.
A biologist at the French-Austrian biotech firm Valneva works on an inactivated whole-virus vaccine against coronavirus disease (COVID-19) in a laboratory in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner
"We believe that this new approval could ... lead to additional marketing authorizations in other regions of the world," Valneva chief Thomas Lingelbach said in a statement.
The vaccine is seen to have two main advantages - it can be stored at similar temperatures to those in a domestic fridge, and it relies on technology that has been used for decades, for instance in some shots against polio, influenza and hepatitis A.
The approach involves growing the virus in a lab, then rendering it completely inactive so it cannot infect cells or replicate in the body, but can still trigger an immune response.
It is seen by some as having the potential to win over people wary of some vaccines which use mRNA technology.
Rx Securities' managing director Samir Devani said even after the mass roll-out, Valneva's vaccine could still be useful if a new variant arises.
"The fact that it is available on hand is good news, although the exact revenue profile beyond the orders already received from the EU and Bahrain remains unclear," he said.
Valneva said in March it expected a positive EMA recommendation this month and had begun manufacturing. It said it has inventory ready for labelling and deployment once it is approved there. read more
Bahrain granted Valneva's vaccine emergency use authorisation in early March.
Earlier this year, the company said early data suggested three doses of its vaccine neutralised the Omicron variant of the virus. read more
https://www.reuters.com/world/uk/britain-gets-sixth-covid-shot-after-valneva-approval-2022-04-14/
REUTERS
April 14, 202210:04 PM GMT+8Last Updated 6 hours ago
Britain gives first European approval to Valneva COVID shot
By Natalie Grover
and Sarah Morland
3 minute read
LONDON/PARIS, April 14 (Reuters) - Britain approved Valneva's (VLS.PA) COVID-19 vaccine on Thursday, becoming the first European country to clear the use of the French firm's shot in a move that boosted its shares by more than 20%.
The go-ahead is the sixth COVID vaccine approval by Britain and comes even though London last September scrapped a 1.4 billion euro ($1.5 billion) deal to buy the Valneva shot, alleging the company was in breach of its obligations under the agreement - which Valneva denied.
The company said it was in discussions to supply up to 25,000 doses to the UK's National Health Service and frontline workers in Scotland. It said talks over a settlement following the UK government's decision to ditch its contract continued.
Announcing the approval, the UK's Medicines and Healthcare Products Regulatory Agency (MRHA) said it was the first, whole-virus inactivated COVID-19 vaccine to gain approval in the UK, adding the shot met safety, quality and effectiveness standards.
However demand prospects could be limited in the UK given the vaccination rate is already relatively high, with about 73% of the population having had two doses and almost 60% having had a booster. The government is also rolling out fourth doses to the vulnerable and the elderly.
"The UK continues to have sufficient supply for its vaccination programme," a Department of Health and Social Care spokesperson said.
Still, the regulatory nod is a boost for the company as the European Medicines Agency (EMA) assesses the vaccine for possible approval. The European Commission has signed an advance deal for up to 60 million doses. read more
ADDITIONAL AUTHORIZATIONS
Valneva's stock jumped more than 20% to their highest since Jan. 5, helping recover ground lost so far this year amid uncertainty about the regulatory approval process.
A biologist at the French-Austrian biotech firm Valneva works on an inactivated whole-virus vaccine against coronavirus disease (COVID-19) in a laboratory in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner
"We believe that this new approval could ... lead to additional marketing authorizations in other regions of the world," Valneva chief Thomas Lingelbach said in a statement.
The vaccine is seen to have two main advantages - it can be stored at similar temperatures to those in a domestic fridge, and it relies on technology that has been used for decades, for instance in some shots against polio, influenza and hepatitis A.
The approach involves growing the virus in a lab, then rendering it completely inactive so it cannot infect cells or replicate in the body, but can still trigger an immune response.
It is seen by some as having the potential to win over people wary of some vaccines which use mRNA technology.
Rx Securities' managing director Samir Devani said even after the mass roll-out, Valneva's vaccine could still be useful if a new variant arises.
"The fact that it is available on hand is good news, although the exact revenue profile beyond the orders already received from the EU and Bahrain remains unclear," he said.
Valneva said in March it expected a positive EMA recommendation this month and had begun manufacturing. It said it has inventory ready for labelling and deployment once it is approved there. read more
Bahrain granted Valneva's vaccine emergency use authorisation in early March.
Earlier this year, the company said early data suggested three doses of its vaccine neutralised the Omicron variant of the virus. read more
https://www.reuters.com/world/uk/britain-gets-sixth-covid-shot-after-valneva-approval-2022-04-14/
Last edited:
- Joined
- Mar 23, 2012
- Messages
- 384
- Points
- 28
The Guardian
Covid-related deaths are rising in England and Wales, though they remain well below the levels seen in previous waves. Photograph: Justin Tallis/AFP/Getty Images
Nicola Davis Science correspondent
@NicolaKSDavis
Thu 14 Apr 2022 14.33 BSTFirst published on Thu 14 Apr 2022 07.38 BST
A Covid-19 vaccine developed by the French pharmaceutical company Valneva has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency, bringing the total number of jabs approved for use in the UK to six.
As the Covid pandemic swept the world, scientists began developing vaccines against it, with the Pfizer/BioNTech jab being the first in the UK to be authorised for emergency use by the MHRA in 2020. Since then the MHRA has approved the Moderna, Oxford/AstraZeneca, Janssen and Novavax vaccines, although, according to NHS England, Janssen and Novavax are not currently available.
The UK’s independent medicines regulator was the first in the world to approve the Valneva product, the MHRA said. Unlike the other approved Covid jabs, the Valneva vaccine is an inactivated whole-virus vaccine, which means the live virus was grown in a laboratory, rendered unable to infect cells, then administered to people to trigger an immune response.
The MHRA said this approach was already being used for flu and polio vaccines and experts have previously suggested that Covid jabs based on the whole virus may result in a broader immune response than those that involve only the spike protein, and may work better against new variants.
Results released by Valneva in October suggested the vaccine could be as effective as the Oxford jab. In addition, it is stable when stored in a standard refrigerator, which could make it easier to distribute than some other Covid jabs.
Prof Sir Munir Pirmohamed, the chair of the independent Commission on Human Medicines, said the commission and its Covid-19 expert working group had carefully considered the evidence and advised that the benefit-risk balance was positive. “The vaccine is approved for use in people aged 18 to 50 years, with the first and second doses to be taken at least 28 days apart.”
Prof Adam Finn, a member of the Joint Committee on Vaccination and Immunisation and the chief investigator on the Valneva clinical development programme, said that while the jab had been approved it was unlikely to be available in the UK soon, as the government had cancelled its contract to buy the vaccine in September.
However, he said the jab could prove more acceptable than others to some people. “The people who could theoretically benefit from it now are unvaccinated 18- to 50-year-olds who want immunisation but are hesitant about currently available vaccines,” he said, adding that the Novavax jab could also appeal to this group.
However, there was another hurdle. “In the UK, no one has yet been offered any choice as to which vaccine they receive,” said Finn, a professor of paediatrics at the University of Bristol.
On Thursday it was also revealed that the MHRA had approved extending the use of the Moderna Covid jab to six- to 11-year-olds in Great Britain, an age group for which it is already authorised in Northern Ireland. At present, children aged five to 17 are only offered the Pfizer/BioNTech vaccine, which is based on similar mRNA technology.
Dr June Raine, the MHRA’s chief executive, said the Moderna vaccine was safe and effective in six- to 11-year-olds, but that the age group was included in the ongoing safety surveillance of all Covid jabs.
“It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise in due course on whether six-to-11s should be offered vaccination with the Covid-19 vaccine made by Moderna as part of the deployment programme,” she said.
The number of deaths involving coronavirus registered each week in England and Wales has continued to increase, although levels remain well below those reached during previous Covid waves.
https://www.theguardian.com/world/2022/apr/14/valneva-approved-to-be-uks-sixth-covid-vaccine
Valneva approved to be UK’s sixth Covid vaccine
Medicines regulator says it is first in world to approve Valneva product
Covid-related deaths are rising in England and Wales, though they remain well below the levels seen in previous waves. Photograph: Justin Tallis/AFP/Getty Images
Nicola Davis Science correspondent
@NicolaKSDavis
Thu 14 Apr 2022 14.33 BSTFirst published on Thu 14 Apr 2022 07.38 BST
A Covid-19 vaccine developed by the French pharmaceutical company Valneva has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency, bringing the total number of jabs approved for use in the UK to six.
As the Covid pandemic swept the world, scientists began developing vaccines against it, with the Pfizer/BioNTech jab being the first in the UK to be authorised for emergency use by the MHRA in 2020. Since then the MHRA has approved the Moderna, Oxford/AstraZeneca, Janssen and Novavax vaccines, although, according to NHS England, Janssen and Novavax are not currently available.
The UK’s independent medicines regulator was the first in the world to approve the Valneva product, the MHRA said. Unlike the other approved Covid jabs, the Valneva vaccine is an inactivated whole-virus vaccine, which means the live virus was grown in a laboratory, rendered unable to infect cells, then administered to people to trigger an immune response.
The MHRA said this approach was already being used for flu and polio vaccines and experts have previously suggested that Covid jabs based on the whole virus may result in a broader immune response than those that involve only the spike protein, and may work better against new variants.
Results released by Valneva in October suggested the vaccine could be as effective as the Oxford jab. In addition, it is stable when stored in a standard refrigerator, which could make it easier to distribute than some other Covid jabs.
Prof Sir Munir Pirmohamed, the chair of the independent Commission on Human Medicines, said the commission and its Covid-19 expert working group had carefully considered the evidence and advised that the benefit-risk balance was positive. “The vaccine is approved for use in people aged 18 to 50 years, with the first and second doses to be taken at least 28 days apart.”
Prof Adam Finn, a member of the Joint Committee on Vaccination and Immunisation and the chief investigator on the Valneva clinical development programme, said that while the jab had been approved it was unlikely to be available in the UK soon, as the government had cancelled its contract to buy the vaccine in September.
However, he said the jab could prove more acceptable than others to some people. “The people who could theoretically benefit from it now are unvaccinated 18- to 50-year-olds who want immunisation but are hesitant about currently available vaccines,” he said, adding that the Novavax jab could also appeal to this group.
However, there was another hurdle. “In the UK, no one has yet been offered any choice as to which vaccine they receive,” said Finn, a professor of paediatrics at the University of Bristol.
On Thursday it was also revealed that the MHRA had approved extending the use of the Moderna Covid jab to six- to 11-year-olds in Great Britain, an age group for which it is already authorised in Northern Ireland. At present, children aged five to 17 are only offered the Pfizer/BioNTech vaccine, which is based on similar mRNA technology.
Dr June Raine, the MHRA’s chief executive, said the Moderna vaccine was safe and effective in six- to 11-year-olds, but that the age group was included in the ongoing safety surveillance of all Covid jabs.
“It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise in due course on whether six-to-11s should be offered vaccination with the Covid-19 vaccine made by Moderna as part of the deployment programme,” she said.
The number of deaths involving coronavirus registered each week in England and Wales has continued to increase, although levels remain well below those reached during previous Covid waves.
https://www.theguardian.com/world/2022/apr/14/valneva-approved-to-be-uks-sixth-covid-vaccine
Similar threads
